SAN FRANCISCO, Aug. 8, 2018 /PRNewswire-PRWeb/ -- Today, Metabiota, the pioneer in epidemic risk modeling, announced
As B&V's BTRIC science partner, Metabiota will work with local and foreign stakeholders to improve public heath capacity in Iraq by helping to detect, diagnose, and report emerging and re-emerging diseases of international concern. This work builds on Metabiota's previous CBEP engagements in the Middle East and will further drive Metabiota's understanding of disease risk and scientific capacity in the region. The BTRIC-Iraq award could generate up to $900,000 for Metabiota over the next 18 months. Metabiota's commitment to building public health capacity in coordination with host country governments was further realized through the award of BTRIC Cameroon ($450,000), where the Metabiota team has worked for over 14 years. As part of this 18-month contract, Metabiota will provide biosafety expertise to inform renovations to Cameroon's National Veterinary Laboratory (LANAVET) and will also provide trainings to bolster biosafety and biosecurity capabilities.
For CTRIC III, Metabiota will support B&V on awarded Task Orders by leading human and veterinary science initiatives that encompass training, research, and biological surveillance in cooperation with partner nations. A One Health approach will be applied to enhance the ability to detect and deter biological threats in a safe and secure manner, ensuing compliance to international standards. Under the CTRIC III Task Order 02, Metabiota will support efforts to strengthen laboratory capacity at the National Public Health Laboratory (NPHL) in Thičs, Senegal. Metabiota will further help develop and institutionalize BS&S Standard Operating Procedures (SOP) in the laboratory environment. Senegalese Task Order has potential to drive $600,000 in revenue for Metabiota, with a 12-month option.
"Metabiota has deep ties to the global health community and has been working hand-in-hand with US Government stakeholders and partner nations for almost a decade," said Mary Guttieri, executive vice president of Science and Microbiology at Metabiota. "As a result, our team knows what it takes to help countries assess risk and facilitate earlier detection of outbreaks. Working with Black & Veatch on these task orders will help us continue to leverage our analytics and deep scientific knowledge to improve the world's resilience to epidemics."
Metabiota is a long-time implementer for DTRA, as well as the United States Agency for International Development (USAID), and has a proven track-record for working with local governments, health agencies, private sector firms and non-profit organizations around the world to build effective teams, develop and implement innovative solutions that achieve high impact results.
Metabiota's platform estimates epidemic preparedness and risk, including the frequency, severity, duration and cost of outbreaks with a powerful combination of risk analytics, historical data, disease scenarios and insights from public health analysts and global epidemiologists. Its newly launched Pathogen Sentiment Index is a ground-breaking tool for estimating public fear and behavioral change driven by infectious disease outbreaks.
DTRA awarded the task orders to Black & Veatch, a leading global engineering consulting and construction company. As the prime integrating contractor, Black & Veatch will design, engineer and deploy systems, processes and technologies to further strengthen reporting, detection and response capabilities.
About Metabiota Metabiota is the pioneer in comprehensive risk analytics that help organizations and countries build resilience to epidemics and protect global public health. Built on a strong foundation of scientific expertise, including a worldwide network of on-the-ground experts, Metabiota delivers actionable, data-driven analytics to help countries and corporations mitigate complex health issues. With a strategic global presence and sustained partnerships, Metabiota's agile approach helps identify, analyze and transfer the risk associated with biological threats. The company's international footprint includes operations in nearly 20 countries and offices in San Francisco, Canada, Sierra Leone, Cameroon and the Democratic Republic of the Congo. For more information, visit http://www.metabiota.com.
About DTRA DTRA safeguards the United States and its allies from weapons of mass destruction (chemical, biological, radiological, nuclear and high explosives) by providing capabilities to reduce, eliminate and counter the threat and mitigate its effects. This combat support agency serves as the intellectual, technical, and operational leader for the Department of Defense in the national effort to combat weapons of mass destruction. Established in 1998, this year DTRA celebrates 20 years of creative solutions through teamwork.
About Black & Veatch Black & Veatch is a leading global engineering, consulting and construction company specializing in infrastructure development in energy, water, telecommunications, and management consulting, federal and environmental markets. Founded in 1915, Black & Veatch develops tailored infrastructure solutions that meet clients' needs and provide sustainable benefits. Solutions are provided from the broad line of service expertise available within Black & Veatch, including conceptual and preliminary engineering services, engineering design, procurement, construction, financial management, asset management, program management, construction management, environmental, security design and consulting, management consulting and infrastructure planning. With $3.2 billion in annual revenue, the employee owned company has more than 100 offices worldwide and has completed projects in more than 100 countries on six continents. The company's Web site address is http://www.bv.com.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All